Production of recombinant HPV11/16 E6/E7-MBP-His6 fusion proteins and their potential to induce cytokine secretion by immune cells in peripheral blood
M Xu, M Zhong, S Feng, Y Xu, X Peng, K Zeng… - Virology Journal, 2024 - Springer
Human papillomavirus (HPV) infection poses a significant threat to public health worldwide.
Targeting the function of HPV E6 and E7 proteins and activating the host immune response …
Targeting the function of HPV E6 and E7 proteins and activating the host immune response …
LALF32‐51‐E7, a HPV‐16 therapeutic vaccine candidate, forms protein body‐like structures when expressed in Nicotiana benthamiana leaves
RJR Yanez, R Lamprecht, M Granadillo… - Plant Biotechnology …, 2018 - Wiley Online Library
High‐risk human papillomaviruses (HPV s) cause cervical cancer, and while there are good
prophylactic vaccines on the market, these are ineffective against established infections …
prophylactic vaccines on the market, these are ineffective against established infections …
Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana
RJR Yanez, R Lamprecht, M Granadillo, B Weber… - PLoS …, 2017 - journals.plos.org
High-risk human papillomaviruses (hr-HPVs) cause cervical cancer, the fourth most common
cancer in women worldwide. A HPV-16 candidate therapeutic vaccine, LALF32-51-E7, was …
cancer in women worldwide. A HPV-16 candidate therapeutic vaccine, LALF32-51-E7, was …
[HTML][HTML] A novel strategy for the purification of a recombinant protein using ceramic fluorapatite-binding peptides as affinity tags
In recent years, affinity fusion-tag systems have become a popular technique for the
purification of recombinant proteins from crude extracts. However, several drawbacks …
purification of recombinant proteins from crude extracts. However, several drawbacks …
[HTML][HTML] The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response
M Granadillo, AB Alfonso, MG Vallespi, A Batte… - Journal of Cellular …, 2016 - Elsevier
Aluminum-containing adjuvants (alum) continue to be the most widely used adjuvants. It is
common knowledge that these adjuvants predominantly induce humoral immunity, but some …
common knowledge that these adjuvants predominantly induce humoral immunity, but some …
[HTML][HTML] Vacunación contra el virus del papiloma humano
A Echeverría, W Martín - Pediatría (Asunción), 2013 - scielo.iics.una.py
El descubrimiento de que ciertas cepas de alto riesgo de los virus de papiloma humano
causan cerca del 100% de cáncer cervical invasivo, disparó una revolución en la …
causan cerca del 100% de cáncer cervical invasivo, disparó una revolución en la …
Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate
M Granadillo, A Batte, AB Alfonso, A Blanco, D Urquiza… - Vaccine, 2019 - Elsevier
Cervical cancer is a global public health problem and human papillomavirus (HPV) 16
accounts for approximately 50% of cases worldwide. Although there are several types of …
accounts for approximately 50% of cases worldwide. Although there are several types of …
LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs
M Granadillo, A Batte, A Blanco, AB Alfonso… - Clinical & Experimental …, 2017 - Springer
One important goal of cancer immunotherapy is to prevent and treat tumor metastasis. We
have previously reported the significant antitumor effect induced by the immunization with …
have previously reported the significant antitumor effect induced by the immunization with …
[HTML][HTML] Obtaining a Recombinant Protein Based on the E7 Antigen of Human Papillomavirus Type 18
N Rodriguez Rodriguez… - Journal of Cancer …, 2022 - fortuneonline.org
Background: Cervical cancer is the fourth most common cancer in women worldwide and
was the leading cause of death among approximately 300 000 cases in 2018. The main risk …
was the leading cause of death among approximately 300 000 cases in 2018. The main risk …
Obtention and characterization of the recombinant simian Interleukin-15 in Escherichia coli for the preclinical assessment of an IL-15-based therapeutic vaccine
Y Rodríguez-Álvarez, K Martínez-Cordovez… - Preparative …, 2017 - Taylor & Francis
ABSTRACT Recombinant simian IL-15 (siIL-15) was obtained for the preclinical assessment
of an anti-human IL-15 vaccine. For this purpose, the cDNA from peripheral blood …
of an anti-human IL-15 vaccine. For this purpose, the cDNA from peripheral blood …